doi: 10.3389/fnut.2025.1581848 Received 23 February 2025 Accepted 22 September 2025 Published 15 October 2025 Volume 12 - 2025 Edited by Roberta Zupo, University of Bari Aldo Moro, Italy Reviewed by Padhmanand Sudhakar, Kumaraguru College of Technology, India Edem E
Less commonly, fewer than 1 percent of patients may experience dizziness, flushing, headaches, or hyperactivity
A longitudinal cohort study conducted from 2014 to 2017, involving 2,081 individuals aged 65 and above with annual follow-up intervals, revealed a significant reduction in depressive symptoms over time
In a phase 2 trial, cagrilintide led to greater weight reductions compared to placebo and liraglutide, with the highest dose achieving a mean weight reduction of 10.8% 1
Nuttall et al.[37] studied the effect of chronic ingestion of therapeutic doses of APAP (1 gram, 4 times per day, for 2 weeks) on serum antioxidant capacity, and found a gradual and progressive decline to a level about 85% of control value
126(Pt 10)21832190